Axsome Therapeutics (AXSM) Return on Capital Employed (2016 - 2026)
Axsome Therapeutics recorded quarterly Return on Capital Employed of 17.09% in Q1 2026, down 33.53% quarter-over-quarter from 12.8% in Q4 2025, and up 6272.0% year-over-year from 0.27% in Q1 2025.
Axsome Therapeutics' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 17.09% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6272.0% year-over-year to 17.09%; the TTM figure through Mar 2026 stood at 17.09% (up 6272.0% YoY), while the FY2025 annual figure was 15.37%, up 6519.0% from the prior year.
- Return on Capital Employed came in at 17.09% for Q1 2026 at Axsome Therapeutics, down from 12.8% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.8% in Q4 2025 to a low of 212.43% in Q1 2022.
- A 5-year average of 76.5% and a median of 75.34% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 15140 bps in 2022 and soared 15548 bps in 2023, its largest moves.
- Axsome Therapeutics' Return on Capital Employed stood at 75.34% in 2022, then soared by 32 bps to 50.87% in 2023, then sank by 65 bps to 83.78% in 2024, then jumped by 85 bps to 12.8% in 2025, then tumbled by 34 bps to 17.09% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 17.09%, 12.8%, and 72.2% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -17.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.09% |
| Dec 31, 2025 | -12.80% |
| Sep 30, 2025 | -72.20% |
| Jun 30, 2025 | -82.91% |
| Mar 31, 2025 | -79.80% |
| Dec 31, 2024 | -83.78% |
| Sep 30, 2024 | -85.38% |
| Jun 30, 2024 | -84.82% |
| Mar 31, 2024 | -69.21% |
| Dec 31, 2023 | -50.87% |
| Sep 30, 2023 | -39.36% |
| Jun 30, 2023 | -45.08% |
| Mar 31, 2023 | -56.95% |
| Dec 31, 2022 | -75.34% |
| Sep 30, 2022 | -76.45% |
| Jun 30, 2022 | -155.98% |
| Mar 31, 2022 | -212.43% |
| Dec 31, 2021 | -157.60% |
| Sep 30, 2021 | -113.89% |
| Jun 30, 2021 | -81.35% |
| Mar 31, 2021 | -61.03% |
| Dec 31, 2020 | -57.83% |
| Sep 30, 2020 | -54.15% |
| Jun 30, 2020 | -54.64% |
| Mar 31, 2020 | -48.79% |
| Dec 31, 2019 | -62.26% |
| Sep 30, 2019 | -107.29% |
| Jun 30, 2019 | -62.48% |
| Mar 31, 2019 | -78.45% |
| Dec 31, 2018 | -282.84% |
| Sep 30, 2018 | -212.36% |
| Jun 30, 2018 | -15.75% |
| Mar 31, 2018 | 55.22% |
| Dec 31, 2017 | 123.97% |
| Sep 30, 2017 | 103.35% |
| Jun 30, 2017 | 84.76% |
| Mar 31, 2017 | 86.38% |
| Dec 31, 2016 | 93.70% |
| Sep 30, 2016 | 75.09% |
| Jun 30, 2016 | 47.74% |
| Mar 31, 2016 | 30.43% |